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etabolic Approach
n Heart Failure
ethinking How We Translate
rom Theory to Clinical Practice*
. H. Wilson Tang, MD, FACC
leveland, Ohio
he concept of metabolic modulation in the treatment heart
ailure has been extensively reviewed in several recent
ublications (1–3). Over the past decades, several dugs that
ave been shown to affect the metabolic processes in the
ailing heart, including carnitine palmitoyl transferase I
nd/or II inhibitors such as etomoxir (4) and perhexiline (5),
ate sodium current inhibitors such as ranolazine (6), and
ong-chain 3-ketoacyl coenzyme A thiolase inhibitors such
s trimetazidine (7). Some of these drugs are believed to
ork by partially inhibiting the oxidation of fatty acids in
schemic myocytes. Because oxidation of glucose requires
ess oxygen per mole of adenosine triphosphate generated,
lucose oxidation is preferable to fatty acid oxidation when
xygen availability is limited in underperfused cardiac tissue.
owever, unlike neurohormonal antagonism, this concept
f supplying “better” fuel to improve myocardial efficiency
as not received wide acceptance. Part of the issue is the lack
f reliable assessment tools to identify the phenotype of
etabolic distress, and part is due to the lack of large-scale
linical trials to support their use. Hence, the majority of
hese agents have found themselves going through a long
nd tedious regulatory approval process for the treatment of
ngina pectoris rather than heart failure.
See page 992
Trimetazidine has been approved for the treatment of
ngina pectoris in most of Europe and Asia (but not in the
.S.), and in some countries trimetazidine is even available
n generic forms. In this issue of the Journal, Fragasso et al.
8) reported the results of a prospective, open-label, parallel
roup, randomized study comparing add-on trimetazidine
ersus conventional therapy in 65 consecutive, mostly non-
iabetic and well-treated patients with symptomatic chronic
ystolic heart failure. The investigators had previously con-
ucted several studies in patients with ischemic cardiomy-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiovascular Medicine, the Cleveland Clinic, Cleve-
and, Ohio. Dr. Tang has previously received honorarium from CV Therapeutics, Inc.
nd previously served as a consultant to Amylin Pharmaceuticals and GlaxoSmith-o
line Pharmaceuticals. He is currently a member of the Speakers’ Bureau for Takeda
harmaceuticals and is a consultant for F. Hoffman La-Roche.pathy, and took a further step to test the effects of
rimetazidine on cardiac and exercise performance in a
ubset of patients suffering from non-ischemic dilated car-
iomyopathy. The results are intriguing—trimetazidine was
ssociated with significant improvement in functional ca-
acity, quality of life, and plasma natriuretic peptide levels
ompared with conventional therapy; the improvement was
qually apparent in patients with non-ischemic and isch-
mic cardiomyopathy. The mean improvement in left ven-
ricular ejection fraction was 7%-U, which is consistent with
rior observations (9) and comparable with that of beta-
drenergic blockers. As in previous studies, trimetazidine
as well tolerated and provoked no hemodynamic dysfunc-
ion.
The observation that trimetazidine reverses left ventric-
lar remodeling in patients with non-ischemic cardiomyop-
thy challenges the longstanding working hypothesis that
rimetazidine counteracts the “metabolic switch” in the
etting of myocardial ischemia. However, the findings may
e consistent with recent work in animal models that
uggests that there is a downregulation of fatty acid oxida-
ion enzymes; the switch to carbohydrate oxidation may
nly be a late-stage phenomenon in the heart failure
henotype, and may not be present in otherwise chronic
ompensated states (10). Furthermore, it cannot be assumed
hat the mechanism of action of trimetazidine in patients
ith non-ischemic cardiomyopathy is solely attributable to
odulation of the metabolic switch. On the other hand,
ubclinical regional myocardial ischemia can present in
atients with nonstenotic epicardial coronary arteries, and
bnormalities in positron emission tomography are com-
only observed in the setting of non-ischemic cardiomy-
pathy (11,12). Whether trimetazidine acts as an anti-
schemic agent in patients without overt myocardial
schemia is still unclear.
This paper raises a more important conceptual question
n an era when development of heart failure drug therapy is
ecoming more challenging (13). To date, reversal of left
entricular remodeling has been the most reliable and
onsistent surrogate marker for heart failure drugs that have
emonstrated mortality benefits (14). Trimetazidine is an
pproved drug with longstanding clinical experience in
reating angina in patients outside of the U.S. It has a good
afety profile and is free of deleterious hemodynamic effects.
lthough there is still debate regarding its role in angina
anagement, multiple clinical studies (all100 subjects per
tudy) have shown short-term and long-term improvement
n left ventricular ejection fraction in patients with heart
ailure who were treated with trimetazidine (9,15–21). The
xact phenotype for those who had a response to trimeta-
idine remain to be clearly identified. However, the prereq-
isite for drug approval in the U.S. mandates a thorough
emonstration of hard end points (composed mainly of
ortality benefits, or morbidity benefits combined withbjective clinical improvement) in large clinical trials. This
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Editorial Comment September 5, 2006:999–1000trategy is appropriate and absolutely necessary for newly
iscovered compounds coming along the research develop-
ent pipeline to ensure public safety and to establish drug
fficacy. However, one may wonder whether a widely used
nd well-tolerated agent (such as trimetazidine) must follow
he same rigorous process. Unless we reconsider our ap-
roach, the promise of these types of medical therapies are
ikely out of reach because of the cost of performing
arge-scale pivotal trials and potential rejection from regu-
atory agencies.
Studies such as this give us an opportunity to reflect on
ow heart failure drugs work and how we should approach
n established drug with a novel therapeutic mechanism in
he challenging environment of drug approval. The risk/
enefit profile of the intervention is already well recognized.
ne can easily make a list of criticisms toward single studies
open-label study, small sample size, single-center study,
ack of clinical outcomes, and so on), and conclude that
urther studies are needed. The challenge is to translate
ecades of theory into clinical practice—does the answer lie
n getting more evidence by conducting larger clinical trials,
nding better ways to characterize the phenotype, or re-
hinking the way we determine how drugs should be made
vailable? What is clear is that in the near future, trimeta-
idine will not likely become an option for treating heart
ailure in clinical practice in the U.S. It is difficult to
econcile the promise of such therapies with the reality that
he barriers to their approval as heart failure drugs seems
nsurmountably high.
eprint requests and correspondence: Dr. W. H. Wilson Tang,
epartment of Cardiovascular Medicine, the Cleveland Clinic,
500 Euclid Avenue, F25, Cleveland, Ohio 44195. E-mail:
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